Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV001817652 | SCV002072184 | uncertain significance | not specified | 2017-09-18 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002478062 | SCV002793170 | uncertain significance | Deficiency of steroid 11-beta-monooxygenase; Glucocorticoid-remediable aldosteronism | 2022-04-13 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001817652 | SCV004028763 | uncertain significance | not specified | 2023-07-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004980737 | SCV005567590 | uncertain significance | Inborn genetic diseases | 2024-11-15 | criteria provided, single submitter | clinical testing | The c.457G>A (p.A153T) alteration is located in exon 3 (coding exon 3) of the CYP11B1 gene. This alteration results from a G to A substitution at nucleotide position 457, causing the alanine (A) at amino acid position 153 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005095284 | SCV005774110 | uncertain significance | not provided | 2024-12-14 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 153 of the CYP11B1 protein (p.Ala153Thr). This variant is present in population databases (rs200151403, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with CYP11B1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1338281). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt CYP11B1 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |